Sucralfate Oral Suspension
NDC Package 68462-827-61

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Sucralfate Oral Suspension (sucralfate) suspension is a medication used to treat ulcers in the intestines. This formulation utilizes a suspension delivery system. Marketed by Glenmark Pharmaceuticals Inc., Usa, this product is identified by NDC 68462-827 and is authorized under FDA application ANDA212141.

Identification & Billing

NDC Package Code
68462-827-61
Package Description
420 mL in 1 BOTTLE
Product Code
68462-827
11-Digit Billing Format
68462082761
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Sucralfate Oral Suspension
Non-Proprietary Name
Sucralfate
Substance Name
Sucralfate
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
SUCRALFATE 1 g/10mL
Pharmacologic Class
Usage Information
This medication is used to treat ulcers in the intestines. Sucralfate forms a coating over ulcers, protecting the area from further injury. This helps ulcers heal more quickly.

Regulatory & Marketing

Labeler Name
Glenmark Pharmaceuticals Inc., Usa
Product Type
Human Prescription Drug
FDA Application #
ANDA212141
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-05-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68462-827-61 identifies a specific commercial package of 420 ml in 1 bottle of Sucralfate Oral Suspension, a human prescription drug labeled by Glenmark Pharmaceuticals Inc., Usa. This suspension is formulated for oral use and contains sucralfate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glenmark Pharmaceuticals Inc., Usa on January 05, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat ulcers in the intestines. Sucralfate forms a coating over ulcers, protecting the area from further injury. This helps ulcers heal more quickly.

How is this Glenmark Pharmaceuticals Inc., Usa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68462082761. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68462-827-61
11-Digit CMS (5-4-2)
68462-0827-61

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.